Viatris Inc. (VTRS)

Generic and branded medicines maker. Read October 3, 2026 from the annual report for the period ending December 31, 2025, filed February 26, 2026. Ranked 35 of the 41 Healthcare companies read so far, by the share within reach now.

The filing states more than 30,000 colleagues in one medicines business across 165 countries, with no count by function or country, so one pattern carries the whole workforce (c).

The figures on this page come from the company's own annual report and from BLS staffing patterns for its industries, never from a roster. They are estimates with a stated method. Nothing here says what the company will do: within reach is not a forecast of jobs lost or of savings.

What follows from the reading

Share of working time within reach of AI, on the long-run pace at four in five: 18% now, 33% at the end of 2027, 41% at the end of 2028, 44% at the end of 2030. By the patterns, the work is about 44% desk work, 14% people work and 42% body work. These are the site's industry estimates weighted by the shares below: estimates with a stated method and range, not a forecast of what the company will do. By the same patterns, at the end of 2028 about 56% of the working time stays with people (conversation, in-person and hands-on work), 37% becomes checking a model's work and 4% could be handed over with lighter checks, from the industries' own figures, not the company's roles.

Headcount

30,000 employees as of December 31, 2025 (stated). The filing states no count by country; it operates in more than 165 countries and territories.

The filing: “The Company operates in more than 165 countries and territories with more than 30,000 employees.”

The workforce as industry patterns

What the filing says about the workforce: More than 30,000 colleagues in more than 165 countries and territories, recorded as 30,000.

Companies read with the same leading pattern

Other companies whose largest staffing pattern is also Pharmaceutical and Medicine Manufacturing, largest first, each read from its own annual report. Within reach now and at the end of 2028, long-run pace, four in five.

• Johnson & Johnson (JNJ, 140,800 employees)18% now, 39% by 2028
• Thermo Fisher Scientific Inc. (TMO, 125,000 employees)19% now, 49% by 2028
• Merck & Co., Inc. (MRK, 75,000 employees)18% now, 41% by 2028
• Pfizer Inc. (PFE, 75,000 employees)18% now, 41% by 2028
• AbbVie Inc. (ABBV, 57,000 employees)18% now, 41% by 2028
• Eli Lilly and Company (LLY, 50,000 employees)18% now, 41% by 2028
• Bristol-Myers Squibb Company (BMY, 32,500 employees)18% now, 41% by 2028
• Amgen Inc. (AMGN, 31,500 employees)18% now, 41% by 2028

What the filing says about AI

16 sentences in the filing name AI. The filing names AI in its glossary and among the emerging technologies whose use in its products, services and operations carries legal, regulatory and reputational risk.

• “AI Artificial intelligence ANDA Abbreviated New Drug Application AOCE Accumulated other comprehensive earnings API Active pharmaceutical ingredients ARV Antiretroviral medicines ASC Accounting Standards Codification ASU Accounting Standards Update Biocon Biocon Limited Biocon Biologics Biocon Biologics Limited, a majority owned subsidiary of Biocon Biocon Biologics Transaction The transaction b...”
• “Bribery Act, Chinese anti-corruption laws and similar worldwide anti-corruption laws, which impose restrictions on certain conduct and may carry substantial fines and penalties. ◦ Our competitors, including branded pharmaceutical companies, and/or other third parties, may allege that we or our suppliers are infringing upon their intellectual property, including in an "at risk launch" situation,...”
• “Incorporating ML, AI and other emerging technologies into our products, services and operations may result in legal and regulatory risks, reputational harm or have other adverse consequences to our business, financial condition or results of operations.”
• “ML and AI-based solutions, including generative AI, are increasingly being used in the pharmaceutical industry, including by us, and we expect to use other systems and tools that incorporate ML or AI-based technologies in the future.”
• “If the analyses that ML or AI-based software assist in producing are deficient or inaccurate, we could be subjected to competitive harm, potential legal liability and brand or reputational harm.”

Its annual reports, year by year

Sentences naming AI in each annual report, counted by one rule, beside the median report in the Index that year. Each count links its filing. Every company, by year and sector

• Fiscal 20210median 0
• Fiscal 20220median 0
• Fiscal 20236median 1
• Fiscal 20246median 4
• Fiscal 202516median 10

Headcount by filing year

As reported in each year's annual report, with the filing. A year marked not read had no figure the reading could take from the report's text.

Limits of this reading

• One pattern by description (c): the filing counts no employees by function or country.
• The headcount is stated as more than 30,000 and recorded as 30,000.

Source: the company's annual report on EDGAR, accession 0001792044-26-000013, the filing. Read by Claude Fable 5.1 under rubric version 1, by the method. A company can write to info@stratussc.com to have its reading checked against its filing.